Boston Scientific to buy Symetis

March 31, 2017

Share:

Medical Devices | Ecublens, Switzerland | Corporate Acquisition

Boston Scientific (NYSE: BSX) has agreed to buy Symetis for $435 million in cash. The developer of minimally invasive heart valve replacement devices planned to go public in 2015, but put the IPO on hold due to poor market conditions, per Reuters. Symetis was valued at around $294 million at the time of the IPO postponement.